VALIDATION OF FGSI SEVERITY SCORE IN PATIENTS DIAGNOSED WITH FOURNIER'S GANGRENE. A RETROSPECTIVE STUDY

Catalin Cosma

doi:10.33695/rojes.v4i1.55

Catalin Cosma SCJU Tg.Mures Chirurgie 1

DOI: https://doi.org/10.33695/rojes.v4i1.55

Keywords: FGSI, FOURNIER'S GANGRENE, NECROTISING FASCITIS

Abstract

Introduction: The Parisian venereologist Jean Alfred Fournier first described Fournier's gangrene in 1883. Fournier's Gangrene Severity Index (FGSI) represents a numerical score that indicates the severity of the disease. It represents a valuable tool for calculating patient outcomes and applying the proper treatment to avoid local complications and high mortality rates.

Material&Method: We conducted a retrospective study from 2010 to 2021 that included all patients diagnosed and treated for Fournier Gangrene (FG) in Surgical Clinic I Emergency County Hospital Tg.Mures. The diagnosis is based on patient history, local clinical examination, and paraclinical tests. Fournier's Gangrene Severity Index (FGSI) was calculated, and we divided the patients based on the FGSI score. One group had scores <9 points, while the other group included patients with a score >9.

Results: We recorded a total number of 23 patients. The main risk comorbidities were ischemic cardiomyopathy at 56.54% (n=13) and typed II diabetes at 43.4% (n=10). The FGSI index score was calculated in all patients with an average of 8.6± 2. 12 patients received a score >9, while 11 patients were ≤9. The overall mortality rate was 56.26% (n=13), with the high-score FGSI group recording mortality of 100%.

Conclusion: Fournier's disease remains rare, with high mortality and morbidity rates. Therefore, early treatment must be applied to ensure proper treatment and a good outcome. FGSI score can be applied in patients to assess the overall severity of the disease and indicate the morbidity and mortality outcomes.

References

1. Sorensen, M.D. and Krieger, J.N. (2016) "Fournier's gangrene: Epidemiology and outcomes in the General US Population," Urologia Internationalis, 97(3), pp. 249–259. Available at: https://doi.org/10.1159/000445695.
2. Chernyadyev, S.A. et al. (2018) “Fournier’s Gangrene: Literature Review and Clinical Cases,” Urologia Internationalis, 101(1), pp. 91–97. Available at: https://doi.org/10.1159/000490108.
3. Singh, A. et al. (2016) “Fournier’s gangrene. A clinical review,” Archivio Italiano di Urologia e Andrologia, 88(3), p. 157. Available at: https://doi.org/10.4081/aiua.2016.3.157.
4. Ballard, D.H. et al. (2020) "Fournier gangrene in men and women: Appearance on CT, ultrasound, and MRI and what the surgeon wants to know," Canadian Association of Radiologists Journal, 71(1), pp. 30–39. Available at: https://doi.org/10.1177/0846537119888396.
5. El-Qushayri, A.E. et al. (2020) "Fournier's gangrene mortality: A 17-year systematic review and meta-analysis," International Journal of Infectious Diseases, 92, pp. 218–225. Available at: https://doi.org/10.1016/j.ijid.2019.12.030.
6. Estrada, O. (2011) "Fournier's gangrene – medical and surgical considerations," Gangrene - Current Concepts and Management Options [Preprint]. Available at: https://doi.org/10.5772/24344.
7. Eke, N. and E., J. (2011) “Fournier’s gangrene,” Gangrene - Current Concepts and Management Options [Preprint]. Available at: https://doi.org/10.5772/24293.
8. Paty R, Smith AD. Gangrene and fournier’s gangrene. Urol Clin North Am. 1992;19:149-62.
9. Laor E, Palmer LS, Tolia BM, Reid RE, Winter HI. Outcome prediction in patients with Fournier's gangrene. J Urol. 1995;154:89-92
10. Yilmazlar T, Ozturk E, Ozguc H, Ercan I, Vuruskan H, Oktay B. Fournier's gangrene: an analysis of 80 patients and a novel scoring system. Tech Coloproctol. 2010;14(3):217-23
11. Roghmann F, von Bodman C, Löppenberg B, Hinkel A, Palisaar J, Noldus J. Is there a need for Fournier's gangrene severity index? Comparison of scoring systems for outcome prediction in patients with Fournier's gangrene. BJU Int. 2012;110(9):1359-65